PART I Item 1. B usiness Overview Atara Biotherapeutics is a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune disease. Tab-cel (tabelecleucel), has received marketing authorization approval under the proprietary name Ebvallo by the European Commission (EC) for commercial sale and use in the European Economic Area (EEA), by the Medicines and Healthcare products Regul...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-108361 | EDGAR | 106K words |
| 2025-03-07 | 2024-12-31 | 0000950170-25-035507 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0000950170-24-037644 | EDGAR | — |
| 2023-02-08 | 2022-12-31 | 0000950170-23-002185 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001564590-22-007633 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009854 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007027 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001564590-19-004275 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001564590-18-003390 | EDGAR | — |
| 2017-03-09 | 2016-12-31 | 0001564590-17-003792 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-276219 | EDGAR | 71K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106550 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072040 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125389 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095533 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056959 | EDGAR | — |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057147 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039820 | EDGAR | — |
| 2023-05-08 | 2023-03-31 | 0000950170-23-018820 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023248 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0000950170-22-015536 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001564590-22-018253 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-16 | 0001193125-26-108344 | EDGAR | 2K words |
| 2026-03-12 | 0001193125-26-103127 | EDGAR | — |
| 2026-03-03 | 0001193125-26-086793 | EDGAR | — |
| 2026-02-23 | 0001193125-26-062534 | EDGAR | — |
| 2026-01-12 | 0001193125-26-010342 | EDGAR | — |
| 2026-01-02 | 0001193125-26-000907 | EDGAR | — |
| 2025-11-12 | 0001193125-25-276209 | EDGAR | — |
| 2025-10-07 | 0001193125-25-232117 | EDGAR | — |
| 2025-09-04 | 0000950170-25-112898 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106533 | EDGAR | — |
216 total filings indexed. 184 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001604464 |
| Ticker | ATRA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.atarabio.com |
| Listed | 2014-10-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report